Neonatal Jaundice Clinical Trial
— BUBOOfficial title:
Use of "BUBOLight®" Device as an Innovative Phototherapy Device for the Treatment of Newborn's Jaundice. A Monocentric, Descriptive Pilot Study, for the Feasibility, Safety and Tolerance of the BUBOLight® Device
About 50% of full-term newborns and 80% of premature infants develop jaundice which is due to hyperbilirubinemia. In the majority of cases, jaundice disappears naturally without treatment within three weeks of birth, but the bilirubin level may remain too high, which can lead to a serious neurological disease: kernicterus. To avoid this, a therapeutic management must be instituted, and in some cases, one or more phototherapy sessions (PT) may be prescribed. The aim of this trial is to evaluate the safety and level of satisfaction of parents and healthcare team with one innovative device for phototherapy BUBOLight® included two removable strips of luminous textile incorporating optical fibers. 10 newborns requiring phototherapy, will be illuminated during four hours in one session of PT Bilirubin levels is taken at the start of phototherapy H0 and Controls are made at H+6 hours.
Status | Recruiting |
Enrollment | 15 |
Est. completion date | October 2023 |
Est. primary completion date | October 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 30 Days |
Eligibility | Inclusion Criteria: - At time of birth, infant is > 35 weeks gestation - Presence of jaundice confirmed by measurement of bilirubin (transcutaneous bilirubinometer) - Total bilirubinemia rate requiring phototherapy according to National Institute for Health and Clinical Excellence. - Weight =2.500kg - Judged in good health by the investigator following the clinical examination and the medical data (absence of perinatal asphyxia, antibiotic treatment, respiratory disorders) - Absence of fœto-maternal rhesus incompatibility or Kell Exclusion Criteria: - Newborn already treated with phototherapy - Febrile state with body temperature > 37.8°C - Total bilirubinaemia level is equal or excess 100 µmol / L of the indication of phototherapy. - Patient whose jaundice is due to haemolysis, obstruction functional or anatomical. - Minor relative - Newborn requiring exchange transfusion - Newborn with congenital erythropoietic porphyria or a family history of porphyria. - Patient requiring treatment other than phototherapy |
Country | Name | City | State |
---|---|---|---|
France | Hop Jeanne de Flandre Chu Lille | Lille |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Lille | Institut National de la Santé Et de la Recherche Médicale, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of related adverse events (Safety) | Safety is defined as the ability to tolerate 4 hours of phototherapy without - Hyperthermia greater than or equal to 38.5 °C
Hypothermia less than or equal to 36 °C Desaturation in O2 lower than 90% for more than 15 seconds Heart rate greater than 160 / min at calm or less than 80 / min for more than 15 seconds Allergic contact reaction grade =3 |
at the begin of phototherapy (baseline, H0) | |
Primary | Number of related adverse events (Safety) | Safety is defined as the ability to tolerate 4 hours of phototherapy without - Hyperthermia greater than or equal to 38.5 °C
Hypothermia less than or equal to 36 °C Desaturation in O2 lower than 90% for more than 15 seconds Heart rate greater than 160 / min at calm or less than 80 / min for more than 15 seconds Allergic contact reaction grade =3 |
at 2 hours after the beginning of phototherapy (H2) | |
Primary | Number of related adverse events (Safety) | Safety is defined as the ability to tolerate 4 hours of phototherapy without - Hyperthermia greater than or equal to 38.5 °C
Hypothermia less than or equal to 36 °C Desaturation in O2 lower than 90% for more than 15 seconds Heart rate greater than 160 / min at calm or less than 80 / min for more than 15 seconds Allergic contact reaction grade =3 |
at the end of phototherapy exposure (H4) | |
Secondary | Blood bilirubin rate | Bilirubin lowering rate | Baseline and 2 hours after the end of phototherapy (H4+2 hours) | |
Secondary | Transcutaneous bilirubin rate | Bilirubin lowering rate | Baseline (H0) and 2 hours after the end of phototherapy (H4+2 hours) | |
Secondary | EDIN (Newborn Pain and Discomfort Scale) | Variation of the EDIN score between the beginning and 2 hours after phototherapy Minimum value = 0 and maximum value = 15. Above 5 pain is probable, below 5 pain is more likely to be discomfort than pain. | Baseline (H0) and 2 hours after the end of phototherapy (H4+2 hours) | |
Secondary | Perceptions of parents with the use of device | Validated survey at the end of treatment (comfort, heat, humidity, ease of breastfeeding, proximity and possibility of contact with the baby) | 2 hours after the end of phototherapy (H4+2 hours) | |
Secondary | Perceptions of the health team with the use of the device | Validated survey at the end of treatment (comfort, heat, humidity, ease of breastfeeding, proximity and possibility of contact with the baby) | 2 hours after the end of phototherapy (H4+2 hours) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02222805 -
Effect of Timing of Umbilical Cord Clamping on Anaemia at 8 and 12 Months and Later Neurodevelopment
|
N/A | |
Completed |
NCT01622699 -
Implementation of a Transcutaneous Bilirubinometer
|
N/A | |
Completed |
NCT00692224 -
Efficacy of Zinc in Reducing Hyperbilirubinemia Among High Risk Neonates - A Double Blind Randomized Trial
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06080971 -
Persistent Neonatal Jaundice on Neonates and Childern
|
||
Recruiting |
NCT06075290 -
the Difference of Follow-up Methods of Neonatal Jaundice
|
||
Recruiting |
NCT05955144 -
Clinical Validation of the Screening Tool Picterus JP Using Different Smartphones
|
N/A | |
Recruiting |
NCT05127070 -
Evaluating the NeoTree in Malawi and Zimbabwe
|
||
Completed |
NCT02774434 -
Efficacy Study of the Draeger Jaundice Meter (JM-105) in Neonates of ≥ 24 Weeks of Gestational Age
|
N/A | |
Completed |
NCT03306004 -
Neonatal Jaundice: Knowledge, Attitudes and Practices of Mothers and Medical Trainees and Providers in and Around Ogbomosho
|
N/A | |
Terminated |
NCT05365399 -
Evaluation of a Smartphone-based Screening Tool for Neonatal Jaundice in a Ugandan Population
|
N/A | |
Recruiting |
NCT03933423 -
Home Based Phototherapy for Neonatal Jaundice
|
N/A | |
Recruiting |
NCT06087874 -
Preventive Effect of Perinatal Oral Probiotic Supplementation (POPS) on Neonatal Jaundice
|
Phase 2 | |
Recruiting |
NCT06399146 -
Evaluation of Bilirubin Estimates in Newborns From Smartphone Digital Images in a Population in Botswana
|
N/A | |
Recruiting |
NCT03183986 -
Comparison of the Efficacy of Phototherapy Using Blue LED's With Wavelength 478 vs. 459 nm.
|
N/A | |
Withdrawn |
NCT00917007 -
Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis
|
||
Completed |
NCT06227624 -
Role of Oral Zinc in Reducing Neonatal Indirect Hyperbilirubinemia
|
Phase 3 | |
Completed |
NCT04418180 -
Fenofibrate Therapy in Pathological Unconjugated Hyperbilirubinemia in Full Term Infants
|
N/A | |
Completed |
NCT04433923 -
Aluminium Foil as an Adjuvant to Phototherapy for Pathological Unconjugated Hyperbilirubinaemia in Full Term Infants
|
N/A | |
Completed |
NCT06386731 -
Continuous Versus Intermittent Phototherapy in Treatment of Neonatal Jaundice
|
N/A | |
Not yet recruiting |
NCT05475223 -
End Tidal Carbon Monoxide (ETCO): - A Tool to Aid Identification of Neonatal Hemolysis
|
N/A |